Marion Hord, MD
Family Medicine · Stuttgart, ARNPI 1235194481
Payments from drug & device makers
Across 121 payments — averaging $14.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$277
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$225
- AbbVie$204
- Pfizer$133
- Novo Nordisk$127
- Takeda Pharmaceuticals U.S.A., Inc.$116
- plus $709 from 19 others
What the payments were for
- Food & beverage$1,77799%
- Education$131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 19 | $277 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $225 |
| AbbVie(2 entities) | 13 | $204 |
| Pfizer | 10 | $133 |
| Novo Nordisk | 9 | $127 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $116 |
| Corium, LLC | 3 | $78 |
| Merck | 4 | $74 |
| Amgen | 5 | $60 |
| AstraZeneca | 4 | $54 |
| Johnson & Johnson | 4 | $49 |
| Mylan Specialty L.p. | 2 | $39 |
| Novartis | 3 | $38 |
| Lilly USA, LLC | 3 | $37 |
| Eisai Inc. | 2 | $35 |
| Dexcom, Inc. | 2 | $35 |
| Shire North American Group Inc | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Teleflex LLC | 1 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Esperion Therapeutics, Inc. | 2 | $24 |
| Radius Health, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $11 |
How this compares
$1,790 in reported general payments places this provider in the 70th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 266 | $157,862 |
| JardianceEmpagliflozin | 147 | $117,591 |
| MounjaroTirzepatide | 85 | $87,445 |
| XareltoRivaroxaban | 150 | $73,692 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 106 | $70,967 |
| EntrestoSacubitril/Valsartan | 75 | $59,666 |
| OzempicSemaglutide | 47 | $44,602 |
| LinzessLinaclotide | 46 | $23,916 |
| Breo ElliptaFluticasone/Vilanterol | 52 | $20,547 |
| ViberziEluxadoline | 13 | $19,872 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $19,214 |
| MyrbetriqMirabegron | 43 | $18,576 |
| JanuviaSitagliptin Phosphate | 26 | $14,469 |
| FarxigaDapagliflozin Propanediol | 19 | $10,917 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $10,839 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $133 | $164,072296 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $277 | $102,353181 claims |
| Lilly USA, LLCMounjaro | $37 | $87,44585 claims |
| Johnson & JohnsonXarelto | $49 | $73,692150 claims |
| NovartisEntresto | $38 | $59,66675 claims |
| Novo NordiskOzempic, Levemir | $127 | $47,39961 claims |
| AbbVieLinzess, Viberzi | $204 | $43,78859 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $54 | $34,74470 claims |
| MerckJanuvia | $74 | $14,46926 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $116 | $5,00011 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $24 | $4,53314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Stuttgart
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
- Vonda HouchinHarrisburg$206K
- Glenn GibbonsFort Smith$179K
- Christopher BrownJonesboro$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.